Myriad Genetics (MYGN) announced a collaboration with GSK (GSK) aimed at improving access to homologous recombination deficiency, HRD, diagnostic testing for high-grade serous ovarian cancer, HGSOC, patients. A new sponsored testing program leveraging Myriad’s MyChoice HRD Plus and MyChoice CDx Plus Tests is now available in Argentina, Brazil, Chile, Colombia, Egypt, Netherlands, Saudia Arabia, Singapore, and United Arab Emirates. “Our collaboration with GSK is an important step forward in providing critical genetic insights that can help clinicians guide more personalized ovarian cancer treatment decisions,” said Patrick Burke, PhD, EVP of Strategy and Innovation, Myriad Genetics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics launches new Universal Plus Panel for Foresight Carrier Screen
- Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
- Myriad Genetics Proposes Settlement in Shareholder Lawsuits
- Myriad Genetics announces RiskScore study results published
- Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool